ERRATUM

A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development

S Castillo-Lluva, L Hontecillas-Prieto, A Blanco-Gómez, M del Mar Sáez-Freire, B García-Cenador, J García-Criado, M Pérez-Andrés, A Orfao, M Cañamero, JH Mao, T Gridley, A Castellanos-Martín and J Pérez-Losada

Correction to: Oncogene (2015) **34,** 4777–4790; doi:10.1038/onc.2015.224; published online 22 June 2015

Following the online publication of this article we were notified that the headings Snai2 WT^{ERBB2+} and Snai2 KO^{ERBB2+} in Table 1 had been inserted in the incorrect columns. The corrected table appears overleaf.

We apologise for any inconvenience caused by this error.

This error has now been rectified, and the corrected article appears in this issue. The html and online pdf versions have also been rectified, and now carry the corrected paper.

Table 1. Pathophenotypes studied in nulliparous and parous Snai2 WT^{ERBB2+} and Snai2 KO^{ERBB2+} female mice

			Snai2 WT^{ERBB2+}	Snai2 KO^{ERBB2+}	P-value
A. Temporal stages					
Tumor latency (weeks)					
Latency interval (n)	Nulliparous		28.8–90.9 (n = 41)	29.7–114 (n = 33)	
	Parous		21.6–61 (n = 24)	13.1–80.8 (n = 45)	
Median (IR)	Nulliparous		47.7 (13.8)	54.1 (21.04)	0.0127
	Parous		40 (14.82)	40.4 (13.21)	NS
		P-value	0.0038	0.0004	
Duration of disease (weeks)					
Disease interval (n)	Nulliparous		4.28–23.86 (n = 36)	4.57–21.14 (n = 22)	
	Parous		6.7–20 (n = 24)	5.14–22.29 (n = 45)	
Median (IR)	Nulliparous		12.9 (12.75)	10.36 (10.39)	NS
	Parous		13.3 (7.46)	11.6 (5.14)	NS
		P-value	NS	NS	
Lifespan (weeks)					
Lifespan interval (n)	Nulliparous		39.4–90.9 (n = 41)	38.3–114 (n = 32)	
	Parous		20–79.1 (n = 24)	32.1–93 (n = 45)	
Median (IR)	Nulliparous		60.42 (14.28)	66.14 (32.93)	0.0145
	Parous		53.38 (17.07)	50 (16.14)	NS
		P-value	0.0089	0.0009	
B. Tumor traits					
Tumor number					
Incidence percentage (rate)	Nulliparous		87.8% (36/41)	66.67% (22/33)	0.0453
	Parous		87.5% (21/24)	76,09% (35/46)	NS
		P-value	NS	NS	
Multiplicity (2 or more)	Nulliparous		88.89% (32/36)	59.09% (13/22)	0.0204
	Parous		90.48% (19/21)	94.29% (33/35)	NS
		P-value	NS	0.0017	
Median (IR)	Nulliparous		3 (2)	1 (3)	0.0012
	Parous		3 (4)	3 (3.25)	NS
		P-value	NS	0.0076	
Local growth rate					
Median (IR; n)	Nulliparous		0.32 (0.17; n = 59)	0.33 (0.136; n = 26)	NS
	Parous		0.24 (0.21; n = 46)	0.32 (0.27; n = 72)	NS
		P-value	NS	NS	
Metastasis					
Incidence % (rate)	Nulliparous		63.64% (21/33)	50% (9/18)	NS
	Parous		90.47% (19/21)	61% (20/33)	0.0276
		P-value	0.0535	NS	
Multiplicity (2 or more)	Nulliparous		100% (21/21)	100% (9/9)	NS
	Parous		78.9% (15/19)	90% (18/20)	NS
		P-value	0.0424	NS	
Median (IR)	Nulliparous		5 (8.5)	1 (5.25)	NS
	Parous		8 (18)	3 (10)	0.0349
		P-value	NS	NS	

Abbreviations: IR, interquartile range; n, number of mice; NS, non-significant P values. Tumor traits were compared with the Mann–Whitney U-test, and the temporal stages of the disease were evaluated using the Kaplan–Meier estimator and the Log-Rank test. The incidence and multiplicity of tumors and metastases were compared with Fisher's exact test. The numbers of mice used in the experiments are shown in the respective figures along the manuscript. The n values shown in the local growth rate represent all tumors analyzed.